The NIH Genomic Data Sharing (GDS) Policy, effective January 25, 2015, governs the sharing of large-scale human and non-human genomic data generated through NIH-funded research. The NIH Data Management and Sharing (DMS) Policy, effective January 25, 2023, complements and enhances the GDS Policy by introducing a unified framework for data management and sharing across all NIH-funded research:
- Integration of Data Sharing Plans:
- Under the DMS Policy, investigators must submit a Data Management and Sharing Plan (DMS Plan) with their funding application. This policy applies to all NIH-funded or NIH-conducted research that generates scientific data and incorporates genomic data sharing requirements.
- Researchers no longer need to submit a separate Genomic Data Sharing Plan; instead, genomic data considerations are addressed within the broader DMS Plan.
- Key Components of a DMS Plan for Genomic Data Sharing:
- Repository Selection:
- Non-human genomic data: can be stored in any widely used repository. See the list of some commonly used repositories here. In addition, the National Library of Medicine provides a Submission Portal to help find the appropriate NIH repository for sequence data.
- Human genomic data: all studies generating human genomic data that fall within the scope of the NIH GDS policy must first register in the Database of Genotypes and Phenotypes (dbGaP), NIH's central repository for human genomic and associated phenotypic data, even if the data will be submitted elsewhere. See the list of some commonly used repositories here. Researchers who have questions about where their data may be deposited should consult with their program officer (Extramural, grants and contracts) or scientific director (NIH Intramural).
- Ethical and Legal Considerations: Aligning with the GDS Policy’s requirements for de-identified and controlled-access human genomic data, the DMS Policy emphasizes ethical considerations and compliance with informed consent for data sharing. Researchers should address the ethical/privacy concerns, or limitations on human genomic sharing in the DMS Plan (i.e., through de-identification, Certificates of Confidentiality, and other protective measures).